Scientific Program - Headache

Print
Please see below the CONy Scientific Program. Please click on the appropriate section (ordered by ABC) to view the relevant program. Please note that the program and timing is subject to change. To view the program timetable, please click here
 
 
Section Heads: Oved Daniel, Israel, Alan Rapoport, USA & Maria Magdalena Wysocka-Bakowska, Poland
FRIDAY, MARCH 23, 2018
Hall B
08:45-10:55
SESSION 9: HEADACHE THERAPY
  Chairs: Elliott Gross, USA & Kristina Mitosek-Szewczyk, Poland
08:45-09:40 Medication overuse headache (MOH) can be treated with preventive medications without detoxification
Capsule: MOH is usually treated with detoxification from the offending agent first. There is evidence that preventive medications work regardless of detoxification.
08:45-08:55
Host: Alan Rapoport, USA
08:55-09:10
Yes: Jack Schim, USA
09:10-09:25 No: Robert Shapiro, USA
09:25-09:40 Discussion and Rebuttals
 
09:40-10:35 The Criteria for the diagnosis of Trigeminal Neuralgia should be changed to allow sensory loss in the trigeminal distribution
Capsule: The diagnosis of TN is based primarily upon paroxysms of pain in thedistribution of the trigeminal nerve, but sensory loss may not be an acceptable finding. Is this concept true?
09:40-09:50
Host: Lars Edvinsson, Sweden
09:50-10:05
Yes: Joanna Zakrzewska, UK
10:05-10:20 No: Stine Maabjerg, Denmark
10:20-10:35 Discussion and Rebuttals
 
10:35-10:55
Lecture: Noninvasive vagus nerve stimulation in primary headaches: Oved Daniel, Israel
 
10:55-11:10 Coffee break
 
11:10-13:20 SESSION 10: NON-PHAMACOLOGICAL TREATMENT FOR HEADACHE
  Chairs: George Chakhava, Georgia
11:10-12:05
Nutraceuticals are safe and effective as migraine treatments
Capsule: People who suffer from headache often prefer nutraceutical treatment over traditional pharmacological approaches, due to fear of possible side effects, drug dependence or addiction. Widespread skepticism persists among doctors about the effectiveness of these treatments.
11:10-11:20
Host: Dimos Mitsikostas, Greece
11:20-11:35 Pro: Jose Miguel Lainez, Spain
11:35-11:50 Con: Maria-Magdalena Wysocka-Bąkowska, Poland
11:50-12:05 Discussion and Rebuttals
   
12:05-13:00 Behavioral therapy is more effective, better tolerated and safer than preventive medications for migraine
Capsule: Medication and psychological intervention are often used in primary headache disorders Are both necessary?
12:05-12:15 Host: Robert Shapiro, USA
12:15-12:30 Yes: Steve Baskin, USA
12:30-12:45 No: Hans Hamburger, The Netherlands
12:45-13:00 Discussion and Rebuttals
   
13:00-13:20
Lecture: Pipeline in Headache Treatment: Alan Rapoport, USA
   
13:20-14:20 Sponsored Symposium (Not for CME) – HALL A
 
14:20-15:05 Lunch Break 
 
15:05-16:55 SESSION 11: HEADACHE THERAPY, OLD AND NEW
  Chairs: Adam Stepien, Poland & Ruta Mameniskie, Lithuania
15:05-16:00
Medical cannabis is effective in chronic headache
Capsule: The use of medical cannabis in patients with chronic headache varies widely, with contradicting data regarding its efficacy in chronic headache subtypes.
15:05-15:15 Host: Messoud Ashina, Denmark
15:15-15:30 Yes: Arieh Kuritzky, Israel
15:30-15:45 No: Dimos Mitsikostas, Greece
15:45-16:00 Discussion and Rebuttals
 
16:00-16:55 Monoclonal antibodies to CGRP will not become first line treatment for the prevention of migraine.
Capsule: CGRP plays a crucial role in migraine pathophysiology. Monoclonal antibodies against CGRP or its receptor are promising new therapies for the treatment of migraine
16:00-16:10 Host: Hartmut Goebel, Germany
16:10-16:25 Pro: Christian Lampl, Austria
16:25-16:40 Con: Lars Edvinsson, Sweden
16:40-16:55 Discussion and Rebuttals
 
16:55-17:10 Coffee Break
   
17:10-19:00
SESSION 12: MIGRAINE, CAUSES AND MANIFESTATIONS
  Chairs: Janusz Wendorff, Poland
17:10-18:05 Head injury can precipitate the onset of migraine
Capsule: Post-traumatic headache may be nonspecific in character. May patients have a symptom pattern indistinguishable from migraine with or without aura?
17:15-17:25 Host: Min Kyung Chu, South Korea
17:25-17:35 Pro: Oved Daniel, Israel
17:30-17:50 Con: Messoud Ashina, Denmark
17:50-18:05 Discussion and Rebuttals
 
18:05-19:00 Episodic vertigo can be a manifestation of migraine, at times, unaccompanied by headache
Capsule: Vestibular migraine is a term used to describe episodic vertigo in migraine patients, but is it a distinct diagnosis, or simply a sensory manifestation of migraine?
18:05-18:15
Host: Maria-Magdalena Wysocka-Bąkowska, Poland
18:15-18:30 Pro: Christian Lampl, Austria
18:30-18:45 Con: Jose Miguel Lainez, Spain
18:45-19:00 Discussion and Rebuttals
 
SUNDAY, MARCH 25, 2018 Hall B
07:00-08:00 E-Poster Presentations
   
08:30-10:30 SESSION 38: POLISH HEADACHE SOCIETY SESSION
  Chair: Ermal Kurmaku, Albania
08:30-09:10 Migraine attacks should be first treated with triptans
 Capsule: Triptans are specific treatment against migraine attack. They are considered to be effective in aborting migraine headache and associated symptoms. However, triptans have several disadvantages that need to be considered. It will be discussed whether triptans should be used as a first line treatment in migraine patients.
08:30-08:40 Host: Wojciech Kozubski, Poland
08:40-08:55 Pro: Magdalena Wysocka-Bąkowska, Poland
08:55-09:10 Con: Ewa Czapinska-Ciepiela, Poland
 
09:10-09:50 Migraine is a risk factor for stroke
 Capsule: Migraine for years was regarded as "vascular headache" and cumulative data linked migraine with vascular events. The relationship could be multidimensional – the diseases are considered to share common underlying mechanisms, to be a risk factor of each other, to be a direct or indirect cause of each other, as well as to be influenced by the drugs used in both conditions. Pros and cons discussions of such interrelationship are now endless debates.
09:10-09:20 Host: Adam Stępień, Poland
09:20-09:35 Pro: Jacek J. Rozniecki, Poland
09:35-09:50 Con: Wojciech Kozubski, Poland
 
09:50-10:30 PFO in migraine: to close or not to close….
 Capsule: The PFO is generally considered to be associated with cryptogenic ischemic stroke in young patients and with migraine especially with aura but it can be difficult to determine the degree to which the PFO is a causative factor. It will be discussed if it should be recommend a comprehensive diagnostic evaluation to exclude other etiologies of PFO associated conditions and proceeding.
09:50-10:00 Host: Jacek J. Rozniecki, Poland
10:00-10:20 Pro: Izabela Domitrz, Poland
10:20-10:40 Con: Adam Stępień, Poland